share_log

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A:修正後委託徵集材料
美股SEC公告 ·  2024/08/21 00:52

牛牛AI助理已提取核心訊息

Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics, Inc.宣佈將於2024年9月3日上午10:00舉行2024年股東年會,會議將通過現場音頻網絡廣播平台進行虛擬會議。提案包括選舉兩名II類董事,傑拉爾德·W·麥克勞林和勞拉·E·本傑明,批准Wolf & Company,P.C.作爲獨立審計公司審計2024年12月31日結束的財政年度,並修改公司的公司章程以減少授權股份和普通股。此外,提案還包括實施股票拆分,批准2021年權益激勵計劃的修正案,限制某些高管的責任以及必要情況下推遲會議並徵求其他委託的提案。董事會建議贊成所有提案。會議還將處理所有其他合適的業務,這些業務可能在股東年會及其連續、推遲或延期方面出現。
Allarity Therapeutics, Inc.宣佈將於2024年9月3日上午10:00舉行2024年股東年會,會議將通過現場音頻網絡廣播平台進行虛擬會議。提案包括選舉兩名II類董事,傑拉爾德·W·麥克勞林和勞拉·E·本傑明,批准Wolf & Company,P.C.作爲獨立審計公司審計2024年12月31日結束的財政年度,並修改公司的公司章程以減少授權股份和普通股。此外,提案還包括實施股票拆分,批准2021年權益激勵計劃的修正案,限制某些高管的責任以及必要情況下推遲會議並徵求其他委託的提案。董事會建議贊成所有提案。會議還將處理所有其他合適的業務,這些業務可能在股東年會及其連續、推遲或延期方面出現。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。